Insmed Incorporated (INSM)
Market Cap | 3.93B |
Revenue (ttm) | 280.82M |
Net Income (ttm) | -723.63M |
Shares Out | 143.06M |
EPS (ttm) | -5.29 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,981,369 |
Open | 26.68 |
Previous Close | 26.97 |
Day's Range | 26.62 - 27.72 |
52-Week Range | 16.04 - 27.72 |
Beta | 1.33 |
Analysts | Strong Buy |
Price Target | 42.00 (+52.84%) |
Earnings Date | Oct 26, 2023 |
About INSM
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis, cystic fibrosis, and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled f... [Read more]
Financial Performance
In 2022, Insmed's revenue was $245.36 million, an increase of 30.19% compared to the previous year's $188.46 million. Losses were -$481.53 million, 10.8% more than in 2021.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for INSM stock is "Strong Buy." The 12-month stock price forecast is $42.0, which is an increase of 52.84% from the latest price.
News

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , Dec. 5, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

Insmed To Present at the Nasdaq 49th Investor Conference
BRIDGEWATER, N.J. , Nov. 29, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,...

Insmed To Present at Two November Conferences
BRIDGEWATER, N.J. , Nov. 8, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, t...

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , Nov. 3, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

Insmed Holds Second Annual Global Day of Good to Benefit Communities Across the Globe
— Company-wide day of service brings more than 700 employees together to volunteer in 25 locations throughout the U.S., Europe, and Japan — BRIDGEWATER, N.J. , Nov. 2, 2023 /PRNewswire/ -- Insmed Inco...

Insmed Ranks No. 1 on Science's 2023 Top Biopharma Employers List
-- Insmed Leads Science Top Employers List for Third Consecutive Year -- BRIDGEWATER, N.J. , Oct. 26, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a m...

Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $79.1 Million for the Third Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 17% Growth Compared to the Third Qu...

Insmed and Google Cloud Collaborate to Transform the Lives of Patients by Harnessing the Power of AI
BRIDGEWATER, N.J. , Oct. 24, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company, today announced a collaboration with Google Cloud to transform the drug discov...

Insmed to Host Third-Quarter 2023 Financial Results Conference Call on Thursday, October 26, 2023
BRIDGEWATER, N.J. , Oct. 12, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

Insmed To Present at Chardan's 7th Annual Genetic Medicines Conference
BRIDGEWATER, N.J. , Sept. 26, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases...

Insmed To Present at the Morgan Stanley 21st Annual Global Healthcare Conference
BRIDGEWATER, N.J. , Sept. 6, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC
—QOL-B Respiratory Domain Shown to Work Effectively as Patient-Reported Outcome Tool in Patients with MAC Lung Disease; to be Proposed to FDA as Primary Endpoint in ENCORE with No Modifications— —Pati...

Insmed Reports Second-Quarter 2023 Financial Results and Provides Business Update
-- ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $77.2 Million for the Second Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 18% Growth Compared to the Secon...

Insmed to Host Second-Quarter 2023 Financial Results Conference Call on Thursday, August 3, 2023
BRIDGEWATER, N.J. , July 20, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,...

Insmed To Present at the Goldman Sachs 44th Annual Global Healthcare Conference
BRIDGEWATER, N.J. , June 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, t...

Insmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference
—Brensocatib Reduced Risk of Exacerbations Irrespective of Disease Severity in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) in Phase 2 WILLOW Subgroup Analysis— —Real-World Cohort Study Sh...

Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"
—Early-Stage Research Pillar Anticipated to Generate at Least Six Investigational New Drug (IND) Applications by End of 2025— —Company Reveals Select Initial Disease Targets for Next-Generation Gene T...

Insmed Reports First Quarter 2023 Financial Results and Provides Business Update
—Enrollment Complete in Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis; Topline Data Readout on Track for Second Quarter of 2024— —Company to Provide Detailed Update on Early...

Insmed to Host Investor and Analyst Event on May 8, 2023
— The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More — BRIDGEWATER, N.J. , April 24, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopha...

Insmed to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 4, 2023
BRIDGEWATER, N.J. , April 20, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases...

Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis
—Topline Data Remains on Track to be Reported in Q2 of 2024— —More than 1,700 Adult Patients Enrolled in Global, Registrational Study of First-in-Class Treatment Candidate— BRIDGEWATER, N.J. , March 3...

Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference
—Data from Retrospective Study Evaluating the Association Between Hospitalization Burden and Delay in Diagnosis of Nontuberculous Mycobacterial (NTM) Lung Disease Among Patients with Chronic Obstructi...

Insmed To Present at Two March Conferences
BRIDGEWATER, N.J. , March 1, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,...

Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
—Patient Screening Complete in Adult Patients in Phase 3 ASPEN Trial of Brensocatib in Bronchiectasis; Topline Data Readout on Track for Second Quarter of 2024— —Company to Share Robust Updates Across...

Insmed to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, February 23, 2023
BRIDGEWATER, N.J. , Feb. 9, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, t...